GlassScriptPhysician profile
Manit Pahuja
NPI 1124768361
$4,214.98
in general payments reported to CMS, 2019-2025
29 companies · $51.85 in 2025
The $51.85 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $302 · 2023: $1,116 · 2024: $2,745 · 2025: $51.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,912.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $718.26 | 2022-2024 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $486.93 | 2022-2024 | |
| Emd Serono, INC. | $464.38 | 2023-2024 | Mavenclad |
| Neurocrine Biosciences, INC. | $418.49 | 2022-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $349.81 | 2023-2025 | |
| Pfizer INC. | $273.79 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $260.80 | 2023-2024 | Ajovy, Austedo Xr |
| Amneal Pharmaceuticals LLC | $176.85 | 2022-2024 | Rytary, Crexont |
| Lilly USA, LLC | $151.41 | 2022-2024 | Kisunla, Emgality, Reyvow |
| Neurelis, INC. | $137.04 | 2022-2024 | Valtoco |
| Biogen, INC. | $128.26 | 2022-2024 | Tysabri, Avonex, Vumerity |
| Celgene Corporation | $95.19 | 2023-2025 | Zeposia |
| Eisai INC. | $62.68 | 2023-2024 | |
| Lundbeck LLC | $62.10 | 2023-2024 | Rexulti, Vyepti |
| Sk Life Science, INC. | $60.50 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $54.87 | 2023-2024 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $51.22 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.27 | 2022-2024 | Hyqvia |
| Tanabe Pharma America, INC. | $39.93 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $37.42 | 2023-2024 | |
| Vanda Pharmaceuticals INC. | $23.81 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $19.94 | 2023 | Relyvrio |
| Acadia Pharmaceuticals INC | $17.29 | 2023 | Nuplazid |
| Azurity Pharmaceuticals, INC. | $17.28 | 2024 | Horizant |
| Janssen Pharmaceuticals, INC | $14.32 | 2022 | |
| Impel Pharmaceuticals INC. | $13.32 | 2023 | Trudhesa |
| Aucta Pharmaceuticals, INC. | $12.44 | 2024 | Motpoly Xr |
| Cycle Pharmaceuticals INC | $10.38 | 2024 | Tascenso Odt |
| Corium, LLC | $9.00 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manit Pahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.